HOME >> BIOLOGY >> NEWS
New paclitaxel analog kills more cancer cells than natural product

A multi-university research team led by Virginia Tech University Distinguished Professor of Chemistry David G.I. Kingston has succeeded in enhancing the structure of paclitaxel (TaxolTM) to make it more effective in killing cancer cells.

Having determined how paclitaxel fits into a cancer cell's reproductive machinery, the team is optimistic that simpler molecules can be designed as future medicines.

Kingston will present the research that brought the team to this point at the 227th Annual Meeting of the American Chemical Society, being held in Anaheim, Calif., March 28 through April 1, 2004.

Paclitaxel, a natural compound from yew trees, is a relatively scarce resource, but synthetic forms and analogs have, so far, been less effective. So scientists have continued to study how the paclitaxel molecule works in order to develop more effective products.

Kingston explains that paclitaxel binds to tubulin, a protein molecule that forms the backbone of microtubules. Microtubules are a cell component whose duties include allowing chromosomes to move into the correct position for the cell to divide into two daughter cells.

"When paclitaxel binds to tubulin, it stabilizes the microtubules and messes up the equilibrium between tubulin and microtubule," says Kingston. "A cell with stable microtubules proceeds to programmed cell death without dividing,"

How does paclitaxel bind to tubulin? There is a binding pocket in the protein into which part of the paclitaxel molecule fits. This binding pocket has been visualized by some elegant electron crystallography experiments carried out by scientists at the Lawrence Berkeley National Laboratory (Nogales et al., Cell, 1999, 96, 79). Paclitaxel consists of a rigid ring system attached to a flexible side chain, but the exact arrangement of the side chain in space is not known. Kingston explains, "The issue has been, what is the shape or orientation of the side chain when pa
'"/>

Contact: Susan Trulove
strulove@vt.edu
540-231-5646
Virginia Tech
29-Mar-2004


Page: 1 2 3

Related biology news :

1. New designed paclitaxel analog kills more cancer cells than natural product
2. Vitamin D analog found to boost radiation
3. Scientists at the Scripps Research Institute discover a therapeutic strategy for "misfolding diseases" analogous to Alzheimers disease
4. An exotic grass kills trees by hijacking their water
5. Cinnamon oil kills mosquitoes
6. Birds show superior listening skills
7. UNC study finds protein in male reproductive tract kills bacteria, may improve fertility
8. Fishing kills Fijian coral reefs
9. Toxin combo common in fish appears capable of impairing motor skills
10. Researchers-again-pinpoint why stress kills
11. Technique kills cancerous cells, leaves healthy cells intact

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New paclitaxel analog kills more cancer cells than natural product

(Date:10/16/2014)... Syncytial Virus causes severe respiratory tract infections and ... year. Scientists at VIB and Ghent University have ... counteract this common virus infection. , Xavier ... that paves the way for the development of ... virus that causes suffering in numerous small children ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
(Date:10/15/2014)... Gauß-Allianz has admitted Johannes Gutenberg University Mainz (JGU) ... science hub continues to maintain a significant nationwide ... , "The acceptance of Johannes Gutenberg University Mainz ... a milestone in the national and international competition ... state of Rhineland-Palatinate can be proud that Mainz ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Sandata Announces Case Study with Quality Care Services, Inc. 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
(Date:10/22/2014)... (PRWEB) October 22, 2014 Physicians ... its cardiovascular pharmacogenetics menu, which enables healthcare providers ... With PCLS’s evidence-based results, healthcare providers are ... optimize their therapy, while minimizing risks for adverse ... U.S., according to the FDA [1] more than ...
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
Cached News: